The Prostate · 2010 · 18 citations · 27 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyMolecular OncologyMetastatic Disease TreatmentOncology PharmacologyProstate CancerAnticancer ActivityCancer Cell Proliferation InhibitionCell Cycle AnalysisCellular Membrane DamageDna Damage InductionGrowth Inhibition AssaysParp InhibitionTherapeutic Growth Inhibition
BACKGROUND: Phenoxodiol, a synthetic analog of Genistein, is being assessed in several clinical studies against a range of cancer types and was shown to have a good efficacy and safety profile. In this study we tested the effects of Phenoxodiol against prostate cancer cell lines. METHODS: Cell-cycle analysis, plasmatic membrane damage, clonogenic assay, comet assay, and Western blot methodologies were employed to assess the effects of Phenoxodiol on prostate cancer cell lines. An in vivo model confirmed the potential therapeutic efficacy of Phenoxodiol when administered orally to tumor bearing mice. RESULTS: Phenoxodiol treatment promoted a marked inhibition of proliferation and loss of colony formation in LNCaP cells in a dose- and time-dependent manner. Similar effects were also observed in the metastatic prostate cell lines PC3 and DU145. Activation of poly(ADP ribose) polymerase 1 (PARP-1) clearly indicates the induction of DNA damage by Phenoxodiol. Oral administration of Phenoxodiol induced a considerable growth inhibition of malignant tumors generated by inoculation of LNCaP cells into Balb/c nu/nu athymic mice. CONCLUSIONS: These data demonstrated that Phenoxodiol promotes apoptosis, as determined by PARP-1 degradation, via mitochondrial depolarization and G1/S cell-cycle arrest thereby confirming that it is active against androgen-dependent and independent prostate cancer cells. Although a precise target for Phenoxodiol has not been identified, these data contribute to our understanding of the mechanism by which this drug promotes cell death in prostate cancer cells, and warrants the continued clinical development of Phenoxodiol as a therapeutic for the treatment of metastatic prostate cancer.
27
Molecular determinants of resistance to antiandrogen therapy
Charlie D. Chen, Derek S. Welsbie, Chris Tran et al. · Nature Medicine · 2003 · 2.3K citations
Medicine, Endocrinology, Urology +17
Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells
Jian‐Zhong Qin, Jeffrey Ziffra, Lawrence Stennett et al. · Cancer Research · 2005 · 338 citations
Medicine, Oncology, Pharmacology +16
Phenoxodiol – an isoflavone analog – induces apoptosis in chemoresistant ovarian cancer cells
Marijke Kamsteeg, Thomas Rutherford, Eva Sapi et al. · Oncogene · 2003 · 182 citations
Medicine, Oncology, Pharmacology +16
Soy Isoflavones in the Treatment of Prostate Cancer
Maha Hussain, Mousumi Banerjee, Fazlul H. Sarkar et al. · Nutrition and Cancer · 2003 · 154 citations
Medicine, Oncology, Pharmacology +16